Defining phenotype reversibility in lysosomal disease: Leveraging a COIN model in mucopolysaccharidosis type VI (MPS VI)MOLECULAR GENETICS AND METABOLISMIF3.52022-02-010PRE
BBB-targeted GAA delivered as gene therapy treats CNS and muscle in Pompe disease model miceMOLECULAR GENETICS AND METABOLISMIF3.52022-02-010PRE
Cell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapiesMOLECULAR THERAPYIF122021-12-0115OAAI